Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agency efforts to standardise benefit:risk assessment progress

This article was originally published in Scrip

Executive Summary

The European Medicines Agency has released results from the first of a five-part project that aims to standardise for the first time the way in which it assesses the benefits and risks of medicines.

You may also be interested in...



Novo Awaits EMA’s Verdict On Oral Form Of Antidiabetic Blockbuster Semaglutide

Alnylam’s Givlaari for acute hepatic porphyria is also among the 14 new products that could get an EU approval recommendation this week.

Blow For Janssen As England's NICE Rejects Depression Spray Spravato

Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Topics

UsernamePublicRestriction

Register

SC008312

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel